Merck generated worldwide sales of $16.6 billion in the second quarter of 2026, representing a 5% increase year-over-year, driven by strong demand in Oncology and Animal Health. Non-GAAP loss per share was $0.13, which included a $2.31 per share one-time charge related to the acquisition of Terns Pharmaceuticals. Keytruda remained the primary growth engine with $8.4 billion in sales, while new product launches like Winrevair contributed $588 million, growing 75% year-over-year.
Note: Merck's FY'25 ended on December 31, 2025. Q2 FY'26 ended on June 30, 2026.
In July 2026, the FDA approved Merck's Lipfendra (enlicitide), marking the market's first once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia. The approval was supported by positive results from the Phase 3 CORALreef clinical trials. Analysts project its peak annual sales could reach $4 billion to $5 billion, establishing a critical new revenue stream for the company's cardiovascular franchise.
Below are key drivers of Merck's value that present opportunities for upside or downside to the current Trefis price estimate:
For additional details, select a division from the interactive Trefis split for Merck at the top of the page.
Merck is a global healthcare leader focused on the research, development, and commercialization of prescription therapeutics, vaccines, and animal health products.
The Pharmaceuticals division constitutes Merck's primary economic engine due to durable intellectual property protection, superior operating margins, and market leadership across immuno-oncology.
Keytruda remains the cornerstone of modern cancer immunotherapy, commanding frontline treatment guidelines across dozens of solid tumor indications. Its extensive clinical trial evidence base, combined with physician familiarity and bundled treatment regimens, establishes an imposing moat that protects market share and supports stable net realizations.
Merck is establishing a durable secondary moat through proprietary vaccines and subcutaneous co-formulations such as Keytruda Qlex, which generated $463 million in Q2 2026 following the establishment of a permanent J-code. By substantially reducing clinical administration times from hours to minutes, Merck creates strong convenience value for healthcare providers, dampening future biosimilar displacement risks.
The commercial landscape for frontline biologics faces rising competition from global partnerships, illustrated by Cipla teaming with Chinese drugmakers like Qilu Pharmaceutical to bring low-cost pembrolizumab biosimilars into Western markets. In response, originator biopharma firms are compelled to shift standards of care toward proprietary combinations and specialized drug delivery mechanisms.
The convergence of personalized genomics with immune checkpoint inhibition is transforming cancer treatment from broad systemic therapies to patient-tailored neoantigen vaccines. Merck's late-stage clinical progress alongside Moderna on intismeran reflects an industry-wide pivot toward custom immunotherapy regimens capable of extending exclusivity moats.
